Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Objectives: The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors.
      Methods: A patient-level simulation model was developed to predict costs and outcomes associated with four biological drugs (abatacept, tocilizumab, rituximab and TNF inhibitors) in the treatment of rheumatoid arthritis. Following lack of efficacy or adverse events, the patients were switched to another biological drug until all four options were exhausted. After that, the patients were assumed to receive a 6th line treatment until death. The patients' baseline characteristics and regression models used in the simulation were based on observational data from the National Register for Biological Treatments in Finland. Direct costs comprised drug costs, administration costs, costs of switching, and outpatient and inpatient care, while indirect costs included disability pension and sick leaves due to rheumatoid arthritis. Several subgroup and deterministic sensitivity analyses were conducted.
      Results: Drug costs were the lowest for rituximab, but when administration costs and costs of switching were included, drug costs were the lowest for TNF inhibitors. Abatacept was associated with the highest drug costs, whereas rituximab was associated with the highest healthcare costs. In total, TNF inhibitors had the lowest direct costs, while rituximab had the highest direct costs. The amount of quality-adjusted life years (QALY) gained ranged from 9.405 for rituximab to 9.661 for TNF inhibitors. TNF inhibitors, abatacept, and tocilizumab were dominant in comparison to RTX.
      Conclusions: TNF inhibitors, abatacept, and tocilizumab had lower costs and higher QALYs than rituximab, and therefore, they were dominant in comparison to rituximab. As TNF inhibitors had the lowest costs and highest QALYs, they were the most cost-effective treatment option.
      Competing Interests: HR has received a fee for speaking from Pfizer. KT has received fees for consultancy from Novartis and Pfizer. KP has received fees for speaking and consultancy from Pfizer, MSD, Abbvie, BMS, Roche, Lilly, Novartis, Sandoz, and Sanofi. DN has received fees for consultancy from AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, and UCB. SH works at ESiOR Oy, which carries out studies, consultancy, education, reporting and health economic evaluations for several pharmaceutical (including companies producing biologic RA drugs), food industry, diagnostics and device companies, hospitals, and academic institutions. ESiOR Oy did not play any role in study design, data collection and analysis, decision to publish and did not provide any financial support to work or author. All other authors have declared no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Scand J Rheumatol. 2017 Sep;46(5):359-363. (PMID: 27931158)
      Ann Rheum Dis. 2017 Mar;76(3):486-490. (PMID: 27432355)
      Springerplus. 2013 Oct 17;2:531. (PMID: 24255834)
      Arthritis Care Res (Hoboken). 2013 May;65(5):718-28. (PMID: 23097311)
      Ann Rheum Dis. 2014 Mar;73(3):529-35. (PMID: 24401994)
      Ann Rheum Dis. 2017 Jun;76(6):1057-1063. (PMID: 28031164)
      Rheumatology (Oxford). 2000 Feb;39(2):122-32. (PMID: 10725061)
      Arthritis Res Ther. 2015 May 22;17:134. (PMID: 25997746)
      J Rheumatol. 2015 Mar;42(3):372-8. (PMID: 25593230)
      Rheumatol Int. 2011 Nov;31(11):1493-9. (PMID: 20473756)
      Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570)
      Ann Rheum Dis. 2015 Feb;74(2):430-6. (PMID: 24297378)
      PLoS One. 2015 Mar 17;10(3):e0119683. (PMID: 25781999)
      Rheumatology (Oxford). 2016 Oct;55(10):1803-11. (PMID: 27354689)
      Arthritis Rheum. 1995 Jun;38(6):727-35. (PMID: 7779114)
      Lancet. 2013 May 4;381(9877):1541-50. (PMID: 23515142)
      Ann Rheum Dis. 2010 Feb;69(2):387-93. (PMID: 19416802)
      Arthritis Res Ther. 2015 Sep 18;17:256. (PMID: 26382589)
      Int J Technol Assess Health Care. 2009 Apr;25(2):181-9. (PMID: 19331709)
      Ann Rheum Dis. 2012 Aug;71(8):1303-8. (PMID: 22294630)
      Rheumatology (Oxford). 2010 Apr;49(4):767-77. (PMID: 20100793)
      J Clin Rheumatol. 2015 Jan;21(1):24-30. (PMID: 25539430)
      Ann Rheum Dis. 2013 Sep 1;72(9):1496-502. (PMID: 23136242)
      Joint Bone Spine. 2013 Jan;80(1):29-33. (PMID: 22459416)
      Rheumatology (Oxford). 2017 May 1;56(5):725-735. (PMID: 28064209)
      Ann Rheum Dis. 2010 Jun;69(6):976-86. (PMID: 20447957)
      PLoS One. 2012;7(1):e30275. (PMID: 22272322)
      Arthritis Rheum. 1996 Jan;39(1):34-40. (PMID: 8546736)
      Ann Rheum Dis. 2017 Jun;76(6):960-977. (PMID: 28264816)
      Arthritis Rheum. 2007 Dec;56(12):3896-908. (PMID: 18050221)
      Arthritis Care Res (Hoboken). 2014 Mar;66(3):464-72. (PMID: 24022870)
      Ann Rheum Dis. 2000 Dec;59(12):954-8. (PMID: 11087698)
      Ann Rheum Dis. 1999 Jan;58(1):11-4. (PMID: 10343534)
      Med Care. 1997 Nov;35(11):1095-108. (PMID: 9366889)
    • Accession Number:
      0 (Antibodies, Monoclonal, Humanized)
      0 (Antirheumatic Agents)
      0 (Biological Factors)
      0 (Tumor Necrosis Factor Inhibitors)
      4F4X42SYQ6 (Rituximab)
      7D0YB67S97 (Abatacept)
      I031V2H011 (tocilizumab)
    • Publication Date:
      Date Created: 20190725 Date Completed: 20200325 Latest Revision: 20200325
    • Publication Date:
      20221213
    • Accession Number:
      PMC6656352
    • Accession Number:
      10.1371/journal.pone.0220142
    • Accession Number:
      31339961